Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong.
Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.00619-17. Print 2017 Nov.
We evaluated the and effects of nikkomycin Z combined with an echinocandin (anidulafungin or micafungin) against two isolates and their lab-derived echinocandin-resistant mutants with FKS1 S645Y and FKS1 S645P. Synergistic effects were observed in all tested strains (fractional inhibitory concentration index, <0.5). Enhanced survival was observed in an immunocompromised murine model (log-rank test, < 0.02). Our study demonstrated the therapeutic potential of nikkomycin Z-echinocandin combinations in managing echinocandin resistance.
我们评估了 nikkomycin Z 与棘白菌素(安尼卡fungin 或米卡fungin)联合应用对两株临床分离株及其实验室获得的棘白菌素耐药突变株(FKS1 S645Y 和 FKS1 S645P)的协同作用和效果。在所有测试的菌株中均观察到协同作用(部分抑菌浓度指数,<0.5)。在免疫功能低下的小鼠模型中观察到生存能力增强(对数秩检验,<0.02)。我们的研究表明 nikkomycin Z-棘白菌素联合应用在管理棘白菌素耐药方面具有治疗潜力。